SHIONOGI & CO., LTD.
- Country
- 🇯🇵Japan
- Ownership
- Public
- Established
- 1878-03-17
- Employees
- 5K
- Market Cap
- -
- Website
- http://www.shionogi.co.jp
Clinical Trials
219
Trial Phases
5 Phases
Drug Approvals
3
Drug Approvals
Flomoxef Sodium for Injection
- Product Name
- 氟吗宁
- Approval Number
- 国药准字HJ20150081
- Approval Date
- Mar 1, 2024
Cefcapene Pivoxil Hydrochloride Granules
- Product Name
- 盐酸头孢卡品酯颗粒
- Approval Number
- 国药准字HJ20210072
- Approval Date
- Sep 9, 2021
Clinical Trials
Distribution across different clinical trial phases (171 trials with phase data)• Click on a phase to view related trials
News
Shionogi Receives Regulatory Clearance for Torii Pharmaceutical Acquisition, Tender Offer Proceeds
Shionogi received a "Notice of Non-issuance of Cease and Desist Order" from Japan's Fair Trade Commission on May 28, 2025, clearing regulatory hurdles for its tender offer to acquire Torii Pharmaceutical.
Single-Dose Baloxavir Significantly Reduces Household Influenza Transmission in Global Phase III Trial
The landmark CENTERSTONE trial demonstrates that a single oral dose of baloxavir marboxil (Xofluza) reduces influenza transmission within households by 32%, marking the first evidence that an antiviral can curb respiratory virus spread.
Shionogi Secures Japan's First ADHD Digital Therapeutic Approval with ENDEAVORRIDE
Shionogi has received Japanese regulatory approval for ENDEAVORRIDE, marking the country's first digital therapeutic application specifically designed for pediatric ADHD patients.
Shionogi Launches First Human Trial of Zatolmilast for Jordan's Syndrome Treatment
Shionogi and Jordan's Guardian Angels announce groundbreaking Phase 2 clinical trial of zatolmilast (BPN14770) for Jordan's Syndrome, marking the first-ever human drug study for this ultra-rare genetic disorder.
Cilcare Secures €40 Million to Advance Cochlear Synaptopathy Treatment
Cilcare has secured €40 million in Series A funding to support clinical trials for CIL001, a treatment for cochlear synaptopathy, also known as 'hidden hearing loss'.
Xofluza Significantly Reduces Influenza Transmission in Phase III Trial
Roche's Xofluza (baloxavir marboxil) significantly reduced influenza transmission within households in a Phase III trial, marking a potential advance in flu control.